AU2001263229A1 - Compositions and methods for administration of pharmacologically active compounds - Google Patents

Compositions and methods for administration of pharmacologically active compounds

Info

Publication number
AU2001263229A1
AU2001263229A1 AU2001263229A AU6322901A AU2001263229A1 AU 2001263229 A1 AU2001263229 A1 AU 2001263229A1 AU 2001263229 A AU2001263229 A AU 2001263229A AU 6322901 A AU6322901 A AU 6322901A AU 2001263229 A1 AU2001263229 A1 AU 2001263229A1
Authority
AU
Australia
Prior art keywords
administration
compositions
methods
active compounds
pharmacologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001263229A
Inventor
Neil P Desai
Patrick Soon-Shiong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
American Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Bioscience Inc filed Critical American Bioscience Inc
Publication of AU2001263229A1 publication Critical patent/AU2001263229A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/724—Devices having flexible or movable element
    • Y10S977/727—Devices having flexible or movable element formed from biological material
    • Y10S977/729—From protein or unit thereof, e.g. enzyme or carboxyl group
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • Y10S977/896—Chemical synthesis, e.g. chemical bonding or breaking
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
AU2001263229A 2000-05-19 2001-05-18 Compositions and methods for administration of pharmacologically active compounds Abandoned AU2001263229A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09574763 2000-05-19
US09/574,763 US6537579B1 (en) 1993-02-22 2000-05-19 Compositions and methods for administration of pharmacologically active compounds
PCT/US2001/015993 WO2001089522A1 (en) 2000-05-19 2001-05-18 Compositions and methods for administration of pharmacologically active compounds

Publications (1)

Publication Number Publication Date
AU2001263229A1 true AU2001263229A1 (en) 2001-12-03

Family

ID=24297532

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001263229A Abandoned AU2001263229A1 (en) 2000-05-19 2001-05-18 Compositions and methods for administration of pharmacologically active compounds

Country Status (4)

Country Link
US (1) US6537579B1 (en)
EP (2) EP2014286A3 (en)
AU (1) AU2001263229A1 (en)
WO (1) WO2001089522A1 (en)

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070116761A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
AU2003230691A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
PL206379B1 (en) 2002-07-15 2010-08-31 Alcon Bioerodible film for ophthalmic drug delivery
AU2003278764C1 (en) 2002-09-06 2010-09-16 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
CN103405405A (en) 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 Compositions and methods of delivery of pharmacological agents
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
EP1701718A4 (en) * 2003-12-23 2009-06-24 Abraxis Bioscience Llc Substituted melatonin derivatives, process for their preparation, and methods of use
WO2005062985A2 (en) * 2003-12-23 2005-07-14 American Bioscience, Inc. Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
CA2551567C (en) * 2003-12-23 2014-04-29 Abraxis Bioscience, Inc. Propofol analogs, process for their preparation, and methods of use
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
WO2005117952A2 (en) 2004-05-14 2005-12-15 Abraxis Bioscience, Inc. Treatment methods utilizing albumin-binding proteins as targets
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
WO2006033679A2 (en) * 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
ES2430373T3 (en) * 2004-06-23 2013-11-20 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) salts for cancer treatment
WO2006026592A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Oral administration of poorly absorbed drugs, methods and compositions related thereto
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
US7495052B2 (en) * 2004-09-15 2009-02-24 Bausch & Lomb Incorporated Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
US20060057216A1 (en) * 2004-09-15 2006-03-16 Salamone Joseph C Low-obscuration image transmitting particulate ocular therapeutic formulations
US20060057215A1 (en) * 2004-09-15 2006-03-16 Raiche Adrian T Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
KR20070084325A (en) * 2004-11-18 2007-08-24 브리스톨-마이어스 스큅 컴퍼니 Enteric coated bead comprising ixabepilone, and preparation thereof
AU2013204188B2 (en) * 2005-02-18 2017-01-12 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
AU2012201568B2 (en) * 2005-02-18 2014-07-31 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
LT2301531T (en) * 2005-02-18 2018-09-25 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8026275B2 (en) 2005-02-18 2011-09-27 Abraxis Bioscience, Llc Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury
US7722581B2 (en) * 2005-04-11 2010-05-25 Gholam A. Peyman Crystalline lens drug delivery
US20060229585A1 (en) * 2005-04-11 2006-10-12 Minu, L.L.C. Drug delivery to the crystalline lens and other ocular structures
JP2008536865A (en) * 2005-04-15 2008-09-11 アルバート・アインシユタイン・カレツジ・オブ・メデイシン・オブ・イエシバ・ユニバーシテイ Vitamin K for prevention and treatment of rash secondary to anti-EGFR therapy
MX2007012688A (en) * 2005-04-15 2008-03-14 Synta Pharmaceuticals Corp Combination cancer therapy with bis(thiohydrazide) amide compounds.
SI3311805T1 (en) 2005-08-31 2020-07-31 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
CA2620389C (en) * 2005-08-31 2014-06-17 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
EP1792543A1 (en) * 2005-11-30 2007-06-06 Unilever N.V. Magnesium fortified food product and additive
EP1792544A1 (en) * 2005-11-30 2007-06-06 Unilever N.V. Zinc fortified food product and additive
DE602006013893D1 (en) * 2005-12-05 2010-06-02 Nitto Denko Corp Polyglutamate-amino acid conjugates and methods
MY148575A (en) 2005-12-28 2013-04-30 Fresenius Kabi Oncology Ltd A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions
BRPI0600285C1 (en) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda nanoparticulate pharmaceutical compounds useful for treating restenosis
DE602007005366D1 (en) * 2006-04-07 2010-04-29 Chimeros Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF B-CELL MALIGNOMES
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7458953B2 (en) * 2006-06-20 2008-12-02 Gholam A. Peyman Ocular drainage device
CA2656613A1 (en) * 2006-07-03 2008-01-10 Genmab A/S Prevention of rash in patients undergoing anti-egfr therapy
CA2660524A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceutical Corp. Compounds for treating proliferative disorders
US20100055459A1 (en) * 2006-08-30 2010-03-04 Liquidia Technologies, Inc. Nanoparticles Having Functional Additives for Self and Directed Assembly and Methods of Fabricating Same
US7939564B2 (en) * 2006-08-31 2011-05-10 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
TW200826926A (en) * 2006-09-11 2008-07-01 Synta Pharmaceuticals Corp Bis (thiohydrazide amides) formulation
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
CA2669820A1 (en) * 2006-11-15 2008-05-22 Abraxis Bioscience, Llc Derivatives of 18-amino substituted analogs of the geldamycin hydroquinon with cytotoxic activity for the treatment of cancer
US7799954B2 (en) * 2006-11-17 2010-09-21 Abraxis Bioscience, Llc Dicarbonyl derivatives and methods of use
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
CN104586815A (en) 2006-12-14 2015-05-06 阿布拉科斯生物科学有限公司 Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
CA2672893C (en) * 2006-12-15 2016-02-23 Abraxis Bioscience, Inc. Triazine derivatives and their therapeutical applications
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
DK2481409T3 (en) 2007-03-07 2018-08-06 Abraxis Bioscience Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
JP5583003B2 (en) 2007-04-02 2014-09-03 セラコス・インコーポレイテッド Benzylglucoside derivatives and uses thereof
WO2008124639A2 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
EP2134740A2 (en) * 2007-04-09 2009-12-23 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
CN101674852A (en) * 2007-04-10 2010-03-17 日东电工株式会社 Multi-functional polyglutamate drug carriers
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
CA2686736A1 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
KR20100017540A (en) 2007-05-09 2010-02-16 닛토덴코 가부시키가이샤 Compositions that include a hydrophobic compound and a polyamino acid conjugate
DK2155254T3 (en) * 2007-05-09 2013-03-04 Nitto Denko Corp Polymer conjugated with platinum drugs
EP2155188B1 (en) * 2007-06-01 2013-10-09 Abraxis BioScience, LLC Methods and compositions for treating recurrent cancer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2009010842A2 (en) * 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
KR101107425B1 (en) 2007-08-23 2012-01-19 테라코스, 인코포레이티드 Benzylbenzene derivatives and methods of use
TW200918099A (en) 2007-09-14 2009-05-01 Nitto Denko Corp Drug carriers
SI2644594T1 (en) 2007-09-28 2017-10-30 Pfizer Inc. Cancer Cell Targeting Using Nanoparticles
FR2922107B1 (en) * 2007-10-10 2010-02-26 Aventis Pharma Sa NEW TAXOID COMPOSITIONS
EP2231169B1 (en) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2009073216A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
EP2853264A1 (en) * 2007-12-24 2015-04-01 Sun Pharma Advanced Research Company Limited Nanodispersion
WO2009111271A1 (en) * 2008-03-06 2009-09-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
US8815953B2 (en) * 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
EP2310006A4 (en) * 2008-07-03 2012-04-25 Mayo Foundation Treating cancer
CA2730734C (en) 2008-07-15 2017-04-25 Theracos, Inc. Deuterated 2,3,4-trihydroxy-tetrahydropyranyl-benzylbenzene compounds having sodium glucose cotransporter inhibitory activity
CA2935838C (en) 2008-08-22 2018-04-17 Theracos Sub, Llc Processes for the preparation of sglt2 inhibitors
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en) * 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8128951B2 (en) * 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
EP3037421A3 (en) 2008-11-25 2016-11-30 University Of Rochester Mlk inhibitors and methods of use
BRPI0922823A2 (en) 2008-12-11 2015-08-18 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR101739598B1 (en) 2009-03-13 2017-06-08 아브락시스 바이오사이언스, 엘엘씨 Combination therapy with thiocolchicine derivatives
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
SI2419732T1 (en) 2009-04-15 2020-03-31 Abraxis Bioscience, Llc Prion-free nanoparticle compositions and methods
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
ES2557453T3 (en) 2009-06-09 2016-01-26 Nantbioscience, Inc. Isoquinoline, quinoline and quinazoline derivatives as inhibitors of Hedgehog signaling
BRPI1011318A2 (en) 2009-06-09 2019-09-24 California Capital Equity Llc triazine derivatives and their therapeutic applications
AU2010258964B2 (en) 2009-06-09 2014-09-11 Nantbio, Inc. Benzyl substituted triazine derivatives and their therapeutical applications
CN102802624A (en) 2009-06-19 2012-11-28 太阳医药高级研发有限公司 Nanodispersion Of A Drug And Process For Its Preparation
CA2772301A1 (en) 2009-08-25 2011-03-03 Abraxis Bioscience, Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
LT2501234T (en) * 2009-11-20 2017-12-11 Tonix Pharma Holdings Limited Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
EP2531173B1 (en) * 2010-02-03 2018-09-26 Oncbiomune, L.L.C. Taxane- and taxoid-protein compositions
TWI438009B (en) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc Taxane pro-emulsion formulations and methods making and using the same
LT2552438T (en) * 2010-03-26 2016-09-26 Abraxis Bioscience, Llc Methods of treatment of hepatocellular carcinoma
KR20190109593A (en) 2010-03-29 2019-09-25 아브락시스 바이오사이언스, 엘엘씨 Methods of enhancing drug delivery and effectiveness of therapeutic agents
CA3087813A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of treating cancer
JP2013525285A (en) 2010-04-08 2013-06-20 サンフォード−バーナム メディカル リサーチ インスティテュート Methods and compositions for enhancing delivery of compounds
KR101752944B1 (en) 2010-05-03 2017-07-03 테이코쿠 팔마 유에스에이, 인코포레이티드 Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
CN103153994B (en) 2010-05-24 2016-02-10 罗切斯特大学 Bicyclic heteroaryl kinase inhibitor and using method
NZ708506A (en) 2010-06-02 2016-08-26 Abraxis Bioscience Llc Methods of treating bladder cancer
KR20190038684A (en) 2010-06-04 2019-04-08 아브락시스 바이오사이언스, 엘엘씨 Methods of treatment of pancreatic cancer
JP6031437B2 (en) 2010-06-07 2016-11-24 アブラクシス バイオサイエンス， エルエルシー Combination therapy for treating proliferative diseases
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
EP2675893B1 (en) 2011-02-18 2019-01-09 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
KR101970342B1 (en) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 Intravascular delivery of nanoparticle compositions and uses thereof
PT2707030T (en) 2011-05-09 2020-05-22 Mayo Found Medical Education & Res Cancer treatments
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
WO2012170384A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
EP2747774A4 (en) 2011-09-09 2015-02-11 Biomed Realty L P Methods and compositions for controlling assembly of viral proteins
AU2012318239B2 (en) 2011-11-01 2015-07-09 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
RU2705998C2 (en) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Use of polymer excipients for lyophilization or freezing of particles
WO2014002108A1 (en) * 2012-06-27 2014-01-03 Amrita Vishwa Vidyapeetham University A core-shell nanostructure on the basis of proteins with corresponding therapeutic agents
MX2014013826A (en) 2012-05-16 2018-04-24 Singh Mewa Pharmaceutical compositions for the delivery of substantially water-insoluble drugs.
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
AU2013295549B2 (en) 2012-07-27 2018-04-19 Izumi Technology, Llc Efflux inhibitor compositions and methods of treatment using the same
JO3685B1 (en) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc Non-aqueous taxane nanodispersion formulations and methods of using the same
EP3967306A1 (en) 2012-10-01 2022-03-16 Mayo Foundation for Medical Education and Research Cancer treatments
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN105101959B (en) 2012-11-05 2018-04-17 南特知识产权控股有限责任公司 The derivative containing cyclic sulfonamide as the inhibitor of hedgehog signal transduction pathway
BR112015010109A2 (en) 2012-11-05 2017-07-11 Nant Holdings Ip Llc substituted indol-5-ol derivatives and their therapeutic applications
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
EP2925319B1 (en) 2012-11-30 2019-01-09 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
MX370519B (en) 2012-11-30 2019-12-17 Novomedix Llc Substituted biaryl sulfonamides and the use thereof.
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
ES2872328T3 (en) 2013-02-11 2021-11-02 Abraxis Bioscience Llc Melanoma treatment methods
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
CA2903454A1 (en) 2013-03-12 2014-10-02 Abraxis Bioscience, Llc Methods of treating lung cancer
WO2014143613A1 (en) 2013-03-13 2014-09-18 Abraxis Bioscience, Llc Methods of treatment of pediatric solid tumor
NZ630213A (en) 2013-03-14 2017-05-26 Abraxis Bioscience Llc Methods of treating bladder cancer
US9550760B2 (en) 2013-03-15 2017-01-24 Nantbioscience, Inc. Substituted indol-5-ol derivatives and their therapeutic applications
HUE047547T2 (en) 2013-03-15 2020-04-28 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
WO2014168845A1 (en) * 2013-04-08 2014-10-16 Igdrasol Method of engineering nanoparticle
KR101329646B1 (en) 2013-05-02 2013-11-14 주식회사 지니스 Targeting-enhancing anticancer nanoparticles and preparation method the same
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices
CN113318239A (en) 2014-06-13 2021-08-31 梅约医药教育及研究基金会 Treating lymphoma
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2015018380A2 (en) 2014-07-03 2015-02-12 Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. Therapeutic nanoparticles and the preparation methods thereof
CN107072968B (en) 2014-09-18 2021-01-12 通尼克斯制药控股有限公司 Eutectic formulation of cyclobenzaprine hydrochloride
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CN107708690B (en) 2015-02-27 2021-09-14 常山凯捷健生物药物研发（河北）有限公司 Pyrimidine derivatives as kinase inhibitors and their therapeutic use
US10527604B1 (en) * 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
WO2016210423A2 (en) 2015-06-25 2016-12-29 Sanford Burnham Prebys Medical Discovery Institute Compositions for delivery to and treatment of atherosclerotic plaques
JP6987644B2 (en) 2015-06-29 2022-01-05 アブラクシス バイオサイエンス， エルエルシー How to treat epithelioid cell tumors
TW201707725A (en) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 Carrier-antibody compositions and methods of making and using the same
WO2017031261A1 (en) 2015-08-20 2017-02-23 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
CA3014531A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Methods for improving the therapeutic index for a chemotherapeutic drug
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
KR20220151022A (en) 2016-09-01 2022-11-11 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Carrier-pd-l1 binding agent compositions for treating cancers
JP2019526579A (en) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Methods and compositions for targeting T cell cancer
MX2019002564A (en) 2016-09-06 2019-09-18 Mayo Found Medical Education & Res Paclitaxel-albumin-binding agent compositions and methods for using and making the same.
KR20230011473A (en) 2016-09-06 2023-01-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Methods of treating pd-l1 expressing cancer
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CA3041049A1 (en) 2016-10-27 2018-05-03 Celgene Quanticel Research, Inc. Bromodomain and extra-terminal protein inhibitor combination therapy
US20200190142A1 (en) 2017-05-02 2020-06-18 Stanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
US10738033B2 (en) 2017-05-31 2020-08-11 Nantbio, Inc. Trk inhibition
US10800760B2 (en) 2017-05-31 2020-10-13 Nantbio, Inc. Trk inhibition
RU2020118594A (en) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. ANTI-CANCER AGENTS
CA3083341A1 (en) 2017-12-11 2019-06-20 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
AU2019239953A1 (en) 2018-03-20 2020-10-15 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
EP3921329A1 (en) 2019-02-04 2021-12-15 University of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
WO2020231855A1 (en) 2019-05-10 2020-11-19 Nant Holdings Ip, Llc Nogapendekin alfa-inbakicept for immune stimulant therapies and treatment of viral infections
AU2020375810A1 (en) 2019-10-28 2022-05-12 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
US11318189B1 (en) 2020-05-13 2022-05-03 Nantcell, Inc. IL-15 agonist drug combinations for immune therapy

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4344934A (en) 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4671954A (en) 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5041292A (en) 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
FR2660556B1 (en) 1990-04-06 1994-09-16 Rhone Poulenc Sante MICROSPHERES, THEIR PREPARATION PROCESS AND THEIR USE.
US5059699A (en) 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5270052A (en) * 1991-04-19 1993-12-14 New England Medical Center Hospitals, Inc. Methods and compositions for treatment of infection by intracellular parasites
ES2148223T3 (en) 1992-03-23 2000-10-16 Univ Georgetown TAXOL ENCAPSULATED IN LIPOSOMES AND METHOD FOR USE.
WO1994010980A1 (en) 1992-11-16 1994-05-26 Corporation Of Mercer University Compositions using microencapsulated neutralizing antibodies
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DE69433723T3 (en) 1993-02-22 2008-10-30 Abraxis Bioscience, Inc., Los Angeles PROCESS FOR IN VIVO ADMINISTRATION OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED THEREFROM
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
AU6833994A (en) 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5731334A (en) 1994-01-11 1998-03-24 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs
RU2127125C1 (en) 1994-03-07 1999-03-10 Дзе Дау Кемикал Компани Biological active and/or target dendrimeric conjugates
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5744460A (en) 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
ATE314843T1 (en) 1996-03-12 2006-02-15 Pg Txl Co Lp WATER SOLUBLE PACLITAXEL PRODRUGS
CN100462066C (en) * 1997-06-27 2009-02-18 美国生物科学有限公司 Novel formulations of pharmacological agents, method for preparation thereof and method for use thereof
ES2324378T3 (en) * 1998-02-05 2009-08-05 Novartis Ag PHARMACEUTICAL COMPOSITION CONTAINING EPOTILONE.

Also Published As

Publication number Publication date
EP1337249A4 (en) 2004-03-31
EP1337249A1 (en) 2003-08-27
EP2014286A2 (en) 2009-01-14
EP2014286A3 (en) 2009-03-18
US6537579B1 (en) 2003-03-25
WO2001089522A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
AU2001260414A1 (en) Pharmaceutical compositions for transdermal administration of anti-inflammatory agents
AU762322C (en) Novel galenic formulations of meloxicam for oral administration
AU2001236457A1 (en) Compounds and compositions for delivering active agents
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
AU4300701A (en) Methods and compositions for administration of therapeutic reagents
AU2001284985A1 (en) Compounds and compositions for delivering active agents
AU2003229084A1 (en) Methods and formulations for the delivery of pharmacologically active agents
AU3216600A (en) Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU2093101A (en) Compositions for efficient release of active ingredients
EP1171117A4 (en) Long term administration of pharmacologically active agents
AU2002243277A1 (en) Methods and compositions for encapsulating active agents
HUP0301921A3 (en) Sustained release pharmaceutical compositions for paranteral administration of hydrophilic compounds
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
AU7389300A (en) Methods of administration of glycopyrrolate compositions
AU2001231000A1 (en) Dry powder formulations of antihistamine for nasal administration
AU5699399A (en) Pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
AU2001241729A1 (en) Protected forms of pharmacologically active agents and uses therefor
AU2001288277A1 (en) Compounds and compositions for delivering active agents
AU1262501A (en) Compositions for transdermal and transmucosal administration of therapeutic agents
AU2001230898A1 (en) Formulations and methods for administration of pharmacologically or biologicallyactive compounds
AU2002216346A1 (en) Cabergoline pharmaceutical compositions and methods of use thereof
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
AU2001221695A1 (en) Solid pharmaceutical compositions for controlled release of active substances